tiprankstipranks
Agilent (A)
NYSE:A

Agilent (A) Stock Price & Analysis

2,700 Followers

A Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$96.48 - $155.35
Previous Close$135.08
Volume736.94K
Average Volume (3M)1.78M
Market Cap
$38.80B
Enterprise Value$40.38B
Total Cash (Recent Filing)$1.67B
Total Debt (Recent Filing)$2.56B
Price to Earnings (P/E)31.9
Beta1.23
Nov 18, 2024
EPS EstimateN/A
Dividend Yield0.69%
Share Statistics
EPS (TTM)4.23
Shares Outstanding291,760,872
10 Day Avg. Volume2,611,282
30 Day Avg. Volume1,784,178
Standard Deviation0.08
R-Squared0.52
Alpha0.00152
Financial Highlights & Ratios
Price to Book (P/B)21.20
Price to Sales (P/S)24.71
Price to Cash Flow (P/CF)29.20
P/FCF Ratio39.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.10
Enterprise Value/Gross Profit11.65
Enterprise Value/Ebitda24.58
Forecast
Price Target Upside5.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say
EarningsOrders grew year-over-year for the first time in seven quarters, showing early signs of recovery.
Market PositionAgilent was the most frequently mentioned company when it comes to specific vendors.
Product DemandSurvey results indicate a constructive outlook for Agilent's capital equipment.
Bears Say
Financial PerformanceFY24 revenue and EPS guidance ranges lowered below consensus.
GuidanceA traded down (14%) post close after management aggressively cut the FY24 guide citing China and weaker Biopharma instrument uptake.
Market EnvironmentThe market environment remains challenging with a slower than expected pace of recovery.
---

Financials

Annual

Ownership Overview

1.52%33.94%43.71%20.83%
43.71% Other Institutional Investors
20.83% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

A FAQ

What was Agilent’s price range in the past 12 months?
Agilent lowest stock price was $96.48 and its highest was $155.35 in the past 12 months.
    What is Agilent’s market cap?
    Currently, no data Available
    When is Agilent’s upcoming earnings report date?
    Agilent’s upcoming earnings report date is Nov 18, 2024 which is in 146 days.
      How were Agilent’s earnings last quarter?
      Agilent released its earnings results on May 29, 2024. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.191 by $0.029.
        Is Agilent overvalued?
        According to Wall Street analysts Agilent’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Agilent pay dividends?
          Agilent pays a Quarterly dividend of $0.24 which represents an annual dividend yield of 0.69%. See more information on Agilent dividends here
            What is Agilent’s EPS estimate?
            Agilent’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Agilent have?
            Agilent has 291,760,860 shares outstanding.
              What happened to Agilent’s price movement after its last earnings report?
              Agilent reported an EPS of $1.22 in its last earnings report, beating expectations of $1.191. Following the earnings report the stock price went down -9.665%.
                Which hedge fund is a major shareholder of Agilent?
                Among the largest hedge funds holding Agilent’s share is PRIMECAP Management Co. It holds Agilent’s shares valued at 290M.
                  ---

                  Company Description

                  Agilent

                  Agilent Technologies, Inc. is an analytical instrumentation development and manufacturing company. The company provides instruments, software, services, consumables, and expertise to address the full range of scientific and laboratory management needs.
                  ---

                  A Company Deck

                  ---

                  A Earnings Call

                  Q2 2024
                  0:00 / 0:00
                  ---

                  A Revenue Breakdown

                  56.43%56.43%22.95%20.62%
                  56.43% Life Sciences and Applied Markets
                  22.95% Agilent CrossLab
                  20.62% Diagnostics and genomics
                  tipranks
                  ---

                  A Stock 12 Month Forecast

                  Average Price Target

                  $141.60
                  ▲(5.04% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"107":"$107","156":"$156","119.25":"$119.3","131.5":"$131.5","143.75":"$143.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$155.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$141.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[107,119.25,131.5,143.75,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.98,134.67384615384614,136.3676923076923,138.06153846153845,139.7553846153846,141.44923076923075,143.14307692307693,144.83692307692309,146.53076923076924,148.2246153846154,149.91846153846154,151.6123076923077,153.30615384615385,{"y":155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.98,133.6430769230769,134.30615384615385,134.96923076923076,135.63230769230768,136.29538461538462,136.95846153846153,137.62153846153845,138.28461538461536,138.9476923076923,139.61076923076922,140.27384615384614,140.93692307692308,{"y":141.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.98,132.36615384615385,131.75230769230768,131.13846153846154,130.52461538461537,129.91076923076923,129.29692307692306,128.68307692307692,128.06923076923076,127.45538461538462,126.84153846153846,126.22769230769231,125.61384615384615,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":118.56,"date":1687478400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.38,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.63,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.26,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.27,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.66,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.36,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.35,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.75,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.83,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.12,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.45,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.98,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bruker
                  Abbott Laboratories
                  Becton Dickinson
                  Bio-Rad Laboratories

                  Best Analysts Covering A

                  1 Year
                  1 Year Success Rate
                  26/32 ratings generated profit
                  81%
                  1 Year Average Return
                  +20.69%
                  reiterated a buy rating 4 months ago
                  Copying Brandon Couillard's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +20.69% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis